Kornimate/medical-research-clean huggingface dataset:
adjunctive effect of erythritol on pocket closure rates

Conditions: Periodontitis; Pocket, Periodontal; Pocket, Gingival

Summary: this clinical trial is studying whether using erythritol powder during non-surgical periodontal treatment (deep cleaning) helps improve gum health in people with severe periodontitis. participants with deep gum pockets (4 mm or more) receive standard treatment alone or standard treatment plus cleaning with erythritol powder. the goal is to evaluate if adding erythritol improves outcomes such as healing of gum pockets, bleeding, plaque levels, and gum attachment compared to standard treatment alone.

this study is testing whether erythritol powder, used during non-surgical periodontal treatment (also known as deep cleaning), can help improve gum health in people with advanced periodontitis (stage 3 or 4). periodontitis is a serious gum infection that damages the soft tissue and bone supporting the teeth. standard treatment includes removing plaque and tartar using manual tools or ultrasonic devices. in this study, gum pockets that are 4 mm deep or more are treated either with standard care alone or with standard care plus a cleaning method that uses air pressure and erythritol powder (a sugar alcohol with antibacterial properties). the goal is to determine whether this additional step leads to improved clinical outcomes. participants are randomly assigned to one of the two treatments. the study tracks improvements in gum pocket depth after 2 and 4 months, as well as other indicators of periodontal health like bleeding and plaque levels. researchers are also evaluating whether factors such as age, sex, smoking status, or diabetes influence treatment response.

Eligibility criteria:
inclusion criteria: adults aged 18 years or older diagnosed with stage 3 or 4 periodontitis according to the 2017 classification presence of at least 12 natural teeth presence of periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth good general health or stable systemic conditions (e.g., controlled diabetes) exclusion criteria: use of antibiotics or anti-inflammatory drugs within 3 months prior to treatment periodontal treatment in the previous 6 months pregnancy or breastfeeding current smokers of more than 10 cigarettes per day allergies or intolerance to erythritol or any materials used in the treatment systemic diseases or conditions that could influence periodontal healing (e.g., uncontrolled diabetes, immunodeficiency) use of medications known to affect periodontal tissues (e.g., phenytoin, cyclosporine, calcium channel blockers)
baduanjin sequential therapy and cardiac function of ami with reduced ef after pci

Conditions: AMI

Summary: acute myocardial infarction (ami) is one of the leading causes of death around the world, with the potential for substantial morbidity and mortality. the increasing evidence indicates that exercise training has beneficial effects on lv remodelling in post-mi patients with greater benefits occurring when training earlier following mi, among which the earliest time for rehabilitation is one week after myocardial infarction. however, the effect of baduanjin sequential therapy for patients after one week of ami has yet to be assessed. therefore, the aim of this study is to assess the impact of baduanjin sequential therapy on cardiac and physical function in patients with ami and reduced ejection fraction after primary pci.


Eligibility criteria:
inclusion criteria: * acute myocardial infarction undergoing primary percutaneous coronary intervention; * aged 18 years or over and under 80 years; * 35% \< lvef \< 50% and lv \< 65mm; * with informed consents exclusion criteria: * severe symptomatic congestive heart failure (killip cardiac function class iii-iv); * malignant arrhythmias (ventricular fibrillation, ventricular tachycardia, frequent multiple source ventricular premature); * uncontrolled hypertension (systolic blood pressure greater than 160mmhg, diastolic blood pressure greater than 100mmhg); * life-threatening diseases with limited life expectancy \<6 months; * inability or difficulty to exercise; * participation in other clinical trials

Keywords: acute myocardial infarction baduanjin percutaneous coronary intervention cardiac function physical function
a very high fiber diet versus a low-carbohydrate diet for weight loss

Conditions: Obesity; Type 2 Diabetes

Summary: using a 2x2 complete factorial design, approximately 140 obese men and women who may or may not have type 2 diabetes will be randomized to one of two conditions (70 in each condition): (a) a high fiber diet, or (b) a low-carbohydrate diet. participants will be instructed to follow their assigned diets for 1 year. outcome measures of interest will include participants' bmi, waist circumference, blood lipids (total, hdl, and ldl cholesterol, and triglycerides), c-reactive protein, and gastrointestinal peptides. participants will be recruited from the loma linda and san bernardino city area in southern california.


Eligibility criteria:
inclusion criteria: * bmi 30.0-42.0 kg/m2 * english-speaking exclusion criteria: * pregnancy * lactation * acute or chronic infection * type 1 diabetes * participation in another trial * active cancers * currently using byetta * currently on weight loss medication * weight loss of more than 4 lbs. within the last 3 months * vegan * active eating disorder * gastrointestinal problems that may be worsened by a high fiber intake

Keywords: obesity type 2 diabetes fiber dietary fiber low-carbohydrate diet high protein diet
safety study in patients who were born small and short and were treated with growth hormone to achieve normal height

Conditions: Infant, Small for Gestational Age

Summary: the purpose of this study is to demonstrate that insulin sensitivity is not different between growth hormone - treated subjects who are small for gestational age (sga) and an sga cohort of subjects matched by gender and body mass index (bmi) who are not treated with growth hormone (gh) and who remain short at final height.

case-control

Eligibility criteria:
inclusion criteria: * patients with sga treated with growth hormone in one of the following genotropin studies (89-041, 89-070/071, 90-079, 90-080/98-8122-011) for at least 3 years and after having stopped gh treatment for 5-10 years * untreated sga (based on birth weight and/or length below -2 standard deviations \[sds\] for gestational age) matched to treated sga by body mass index (+ or = 10%) and gender: * subjects born sga with normal final height (within +/- 1.3 sd of their target height); or * subjects born sga with short stature (height sds \> 1.3 below target at final height). exclusion criteria: * known diabetes type 1 or 2, or 1st degree relative of a patient with diabetes type 2 * familial dyslipidemia

Keywords: small for gestational age, insulin sensitivity index, growth hormone treatment
consequences of anti-interleukin 6 immunotherapy treatment for rheumatoid arthritis on periodontium

Conditions: Rheumatoid Arthritis; Periodontitis

Summary: rheumatoid arthritis and periodontitis are two inflammatory diseases that share many pathophysiological similarities as some inflammatory mediators like tnf-alpha, il-1, il-6, il-17, il-12 et il-17, rank-l, or opg the most severe or progressive forms of rheumatoid arthritis require in 10-30% of cases, the use of biotherapies such as anti-tnf-alpha, anti cd-20 and anti-ll-6. all these treatments results in, among other things, an increased risk of infection, both viral and bacterial. these new biotherapies could have an impact on periodontal status * either by favouring sub gingival colonization of root surfaces by periodontal pathogenic bacteria and initiate periodontitis or exacerbate pre-existing periodontitis, * or a positive modulation of the host response by inhibiting bone resorption of the alveolar process. to date, very few studies have been conducted on this subject which is really a translational research, involving several medical specialties.


Eligibility criteria:
inclusion criteria: * patient over 18 years presenting a rheumatoid arthritis and for which an anti il6 biotherapy treatment is prescribed. * at least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal status * having expressed their written free and informed consent exclusion criteria: * hypersensitivity to any of the following components : tocilizumab, saccharose, polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate * severe or active infections * systemic pathology affecting the immune system including sjögren's syndrome * surgery in the previous month * hiv positive * alcoholic * toxicoman * antibiotic treatment in the last 2 months * legally protected patients

Keywords: periodontitis rheumatoid arthritis anti-interleukin 6 immunotherapy inflammation bacteria periodontal sulci periodontal pockets
a clinical trial evaluating the safety and efficacy of the klox biophotonic system in moderate to severe acne

Conditions: Acne Vulgaris

Summary: the purpose of this study is to evaluate the safety and efficacy of the klox biophotonic system in patients with moderate to severe facial acne vulgaris using a split-face design (treated hemiface vs untreated hemiface).


Eligibility criteria:
inclusion criteria: 1. male or female 16 - 30 years of age. 2. fitzpatrick skin type i through iv. 3. known medical history of active acne vulgaris for at least 6 months. 4. moderate-to-severe facial acne, as defined by: moderate is defined as a patient with an iga of 3 with 20 to 40 inflammatory lesions (papules and pustules) and no more than 1 nodule. severe is defined as a patient with an iga of 4 with a greater than 40 inflammatory lesions with the presence of no more than 2 nodules and/or inflammatory scaring type lesion. also note that all patients should have a similar disease stage on both sides of their face. 5. the patient must have a clinical examination prior to treatment. 6. the patient must have signed the consent form. 7. the patient must be willing to return for follow-up visits. 8. females of child bearing potential must have a negative pregnancy test result at baseline and both male and female patients must be willing to adhere to a birth control method. exclusion criteria: 1. active skin infection on the face. patient must not have active, localized or systemic infection. 2. facial aesthetic procedure, including laser therapy and injectables within the last 6 months. 3. enrollment in another acne study or other dermatological study using light therapy including tanning beds within 120 days of enrollment. patients must not take part or intend to take part in another study liable to interfere with this study whatever the region of the body considered for 30 days prior to the study start and 30 days following completion of the study. 4. history of head and/or neck irradiation. 5. use of a hormonal contraception is prohibited unless the birth control has been stable for the past 3 months. note that patient that are presently taking or have taken in past 30 days cyproterone acetate + ethinyl estradiol (diane-35) are not eligible for this study. 6. any facial dermatological conditions that could hinder or interfere with clinical assessments. 7. immunosuppression and/or cortisone therapy in the past 4 months. 8. bleeding diathesis. 9. medications or supplements affecting coagulation. 10. isotretinoin within the last 24 weeks. 11. pregnant, breast-feeding or pregnancy planned during the trial. 12. history of facial nerve palsy or marked facial asymmetry. 13. history of neuromuscular disorder. 14. prior facial surgery that alters subcutaneous tissues (e.g., rhytidectomy). 15. use of non-acne topical medication that could interfere with study treatment. 16. physical or psychiatric condition the investigator deems would preclude participation in the study. (e.g. polycystic ovary disease) 17. unwillingness to refrain from excess sun exposure or tanning beds during the healing process -
group drum-based music therapy intervention for parkinson's disease/huntington's disease

Conditions: Parkinson Disease; Huntington Disease

Summary: participants in this study (18-89 years) with parkinson's disease or huntington's disease receive drum classes twice a week for 12 weeks (24 lessons). all participants also participate in study visits for assessments before the beginning of the study, at the 6 week mark, at the 12 week mark and at the 18 week mark so that the investigators can assess the short and long term effects of drum classes on hand dexterity, upper extremity function and well-being.

there has been evidence that rhythm-based music therapy interventions may improve motor outcomes for patients with parkinson's disease and huntington's disease, as well as quality of life for both patients and the patients' caregivers. drum-pd, a pilot study investigating the impact of west african drumming on quality of life, symptoms, motor findings, cognition, and mood in parkinson's disease, found trends toward improvement in walking from baseline to 12 weeks and improved quality of life for patients who completed the 6 week drumming intervention. building on this research, the investigators plan to evaluate the impact of a 12-week, twice weekly rhythm-based music therapy intervention called the armstrong rhythm cycle℠, implemented by a board-certified music therapist. the investigators hypothesize that participation in 24 bi-weekly, hour-long music therapy drumming sessions will result in improved motor functioning for patients and better quality of life for patients and the patients' caregivers as compared to baseline before the intervention.

Eligibility criteria:
inclusion criteria: patients with parkinson's disease (pd) and huntington's disease (hd) * ability to give written consent * age 18-90 * clinical diagnosis of probable of clinically established parkinson disease; or huntington disease confirmed by genetic testing (greater than or equal to 36 cag repeats) * ability to move hands, wrists and arms safely for instrument play * presence of study partner who is available for all drum lessons and study assessments study partners: * ability to give written consent * ability to give written consent * age 18-90 * ability to move hands, wrists and arms safely for instrument play exclusion criteria: * pd: hoehn \& yahr stage 5 disease; schwab \& england score 40% or lower * hd: total functional capacity scores between 5 and 13 inclusive * co-morbid diagnosis (broken bones, sprains, severe arthritis, conditions involving paresis) in the judgement of the patient's treating physician that may preclude participant's full ability to participate in the intervention group. * moca scores \<17 * active psychosis or other condition affecting the participants' ability to safely cooperate with study procedures

Keywords: group drumming music therapy motor function quality of life cognition social and emotion caregiver burden
comparison between radiofrequency and balloon compression in the treatment of idiopathic trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: two percutaneous procedures used in the treatment of idiopathic trigeminal neuralgia are analysed. the effects on pain relief, alterations in cutaneous sensibility and olfactory and salivatory functions are analysed as well.

patients diagnosed with idiopathic trigeminal neuralgia, refractory or intolerant to medical treatment, are randomly assigned (after signing a consent form), to receive one of two percutaneous procedures. the patients are evaluated a week before and a week, a month, two months, three months and six months after the surgery. the questionnaires (short-form of the mcgill pain questionnaire - sf-mpq, douleur neuropathique - dn4, neuropathic pain symptom inventory - npsi, brief pain inventory - bpi, global clinical impression - gci, hospital anxiety and depression - had, brief world health organization quality of life questionnaire - whoqol-brief, pain catastrophizing scale - pcs) and tests (quantitative sensory testing - qst, olfactory threshold - ot - and discrimination - od, taste threshold - tt, and salivatory quantification - sq) are applied as follows: * pre-op evaluation: sf-mpq, dn4, bpi, npsi, had, whoqol-brief, pcs, qst, ot, od, tt, sq. * first visit post-op: sf-mpq, bpi, npsi, gci * second visit post-op: sf-mpq, bpi, npsi, gci * third visit post-op: sf-mpq, bpi, npsi, gci * fourth visit post-op: sf-mpq, dn4, bpi, npsi, gci, whoqol-brief, had, pcs, qst, ot, tt, sq. * fifth visit post-op: sf-mpq, dn4, bpi, npsi, gci, whoqol-brief, had, pcs, qst, ot, od, tt, sq. patients with pain recurrence are excluded after the last visit attended. an exploratory analysis is made with 30 patients for a proper sample size calculation during the study.

Eligibility criteria:
inclusion criteria: * idiopathic trigeminal neuralgia * refractory/intolerable medical treatment * pain restricted to second or third trigeminal division exclusion criteria: * secondary trigeminal neuralgia * pain restricted to the first trigeminal division * refuse to participate * unable to comprehend the questionnaires
melodic-based communication therapy for promoting spoken language development in individuals with nonverbal autism

Conditions: Nonverbal and Low Verbal Autism

Summary: the purpose of this study is to determine the efficacy of melodic based communication therapy (m.b.c.t.) for increasing oral expressive skills in nonverbal children with autism spectrum disorders. mbct has previously been shown to facilitate an improvement in expressive vocabulary, verbal imitative abilities, number of vocalizations, and social language development in nonverbal children with autism ages 5-7. however, earlier studies were small and did not examine the effects of m.b.c.t. on a younger and older population. this study will examine its effectiveness across a broader sample group. additionally, this study will examine further predictors of success including but not limited to chronological age, developmental age, the frequency of repetitive/stereotypic behaviors, receptive language score, and social language score.

the study will be a repeated measures design as assessments will be taken at baseline and on a weekly basis (baseline, weeks 1-4). all participants in the study will receive melodic based communication therapy (m.b.c.t.). general procedures involved in (m.b.c.t.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). pictures and objects will be used as stimulus items. the top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. all treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. for the purposes of the study design, the same 25 words will be used for all participants. 4. subjects will be male and female children diagnosed with autism. 5. subjects will be between 3 years 0 months and 10 years 11 months of age. 6. in total, subject participation will last approximately 4 weeks.

Eligibility criteria:
inclusion criteria: * male and female children with autism ages 3-years-0-months to 10-years-11-month who meet the criterion for nonverbal (defined as less than 10 words ever spoken expressively and no functional verbal communication) exclusion criteria: * individuals receiving other language or articulation treatments or therapy at the time of the study, unable to regularly attend four 30 min sessions of therapy weekly for 4 weeks, a history of severe hearing impairment, severe visual impairment/ blindness, a diagnosis of an organic impairment of oral or laryngeal structures, or a signiﬁcant medical illness or condition which would prevent the child's participation in the treatment procedures. these conditions include, but are not limited to cerebral palsy, paraplegia, spina biﬁda, uncontrolled seizures, dysarthria, and amputation of arm(s).

Keywords: mbct nonverbal autism low verbal autism
opioid use disorder treatment linkage at sexual health clinics using buprenorphine

Conditions: Opioid-use Disorder

Summary: this study will examine the effectiveness of opioid use disorder (oud) treatment linkage strategies for patients seen at sexual health clinics. this 3-arm rct will compare usual care vs. patient navigation vs. patient navigation + buprenorphine initiation (uc vs. pn vs. pn+bup).

this study, entitled opioid use disorder treatment linkage at sexual health clinics using buprenorphine (outlast-b), will examine opioid use disorder (oud) treatment linkage strategies for people receiving sexual health services from public clinics and health departments. this three-arm, parallel randomized clinical trial (rct) will compare usual care (uc), vs. referral via patient navigation (pn), vs. patient navigation with buprenorphine initiation (pn+bup). the uc arm will include standard services at the sexual health clinic / city health department. the pn arm will include all uc arm services, with the addition of a patient navigator who will assist the participant in selecting a community oud treatment program, facilitate an intake appointment, help to resolve barriers and coordinate oud treatment entry, and support early retention in oud treatment. the pn+bup arm will include all pn arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to oud treatment in the community. research assessments consisting of a structured interview battery and biomarkers for drug use and sexually transmitted infections will be conducted at baseline, 3-, and 6-month follow-up. selected outcomes will be examined through 12-months via health record linkage methods. the study will examine participant outcomes in the domains of: (1) oud treatment entry and retention, (2) opioid use and related problems (including fatal and non-fatal overdose), and (3) hiv/std-related outcomes.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. opioid use in the past 30 days 3. dsm-5 diagnostic criteria for oud with physiological dependence 4. willing to try buprenorphine treatment. exclusion criteria: 1. current enrollment in oud treatment with buprenorphine, methadone, or extended-release naltrexone 2. clinical contraindication with buprenorphine (e.g., allergy to buprenorphine or naloxone, chronic pain management with opioid agonists) 3. regular use of illicit long-acting opioid agonists (e.g., methadone; due to potential challenges with dose induction) 4. heavy alcohol use that, in the judgement of the prescribing provider, raises a safety concern that precludes eligibility for buprenorphine induction 5. high dose or intravenous benzodiazepine misuse 6. pregnancy (due to special needs; will be treated outside of the study) 7. unstable medical or psychiatric illness (e.g., psychosis or active suicidal ideation) 8. inability to provide informed consent (e.g., failure to pass consent quiz)